Cortexyme Inc (NASDAQ:CRTX) shares are trading lower after the company's Phase 2/3 GAIN trial did not meet its co-primary endpoints.

See Also: Why Cortexyme Shares Are Plunging 70% After Hours

Cortexyme is a clinical-stage biopharmaceutical company developing a disease-modifying therapeutic approach to treat Alzheimer's and other degenerative diseases. Its approach is based on the seminal discovery of the presence of Porphyromonas gingivalis or P. gingivalis, and its secreted toxic virulence factor proteases called gingipains.

Cortexyme has a 52-week high of $121.98 and a 52-week low of $14.13.